Covered Stent Market: as endovascular aneurysm repair displaces open surgery as the standard of care for abdominal aortic aneurysm, covered stent grafts shift from a treatment reserved for surgically fit patients into the default first-line option for most anatomies, so fenestrated and branched graft engineering becomes the primary axis of competition, and vendors that expand the treatable anatomy pool to complex juxtarenal and thoracoabdominal configurations capture the patient population that open repair previously left untreated.

The global covered stent market size was USD 4.21 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as endovascular aneurysm repair displacing open surgery as the standard of care for abdominal aortic aneurysm, fenestrated and branched graft technology expanding the treatable anatomy pool to complex juxtarenal and thoracoabdominal configurations, and continued FDA approval of expanded sizing and design options that broaden patient eligibility for existing device platforms. The first driving factor is the multi-decade clinical shift from open surgical aneurysm repair to endovascular aneurysm repair as the default treatment approach for patients with suitable anatomy. Endovascular repair offers materially lower peri-operative mortality and faster recovery than open surgery for eligible patients, and this clinical advantage has driven sustained conversion of the addressable aneurysm repair procedure volume toward covered stent graft technology. The second driving factor is fenestrated and branched graft engineering, which has extended endovascular treatment eligibility to complex juxtarenal and thoracoabdominal aneurysms that previously required high-risk open repair or were treated as unsuitable for intervention. W. L. Gore received FDA approval in March 2025 for four new large-diameter tapered designs for its GORE TAG Conformable Thoracic Stent Graft, expanding the anatomical range treatable with the existing platform without requiring a new device category. The third driving factor is continued FDA approval of expanded sizing, tapering, and design variants that broaden the patient population eligible for already-established covered stent graft platforms. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single FDA-approved covered stent graft platform widens its own addressable patient population as new sizing and design variants are added to the same core product line, letting one established platform capture incremental complex-anatomy procedure revenue without a new device category approval. Once a covered stent graft platform earns its first FDA approval, each additional sizing variant, tapered design, or fenestration configuration added to that platform extends its treatable anatomy range without requiring the vendor to establish an entirely new product category, so the value of an approved platform compounds as its design variant menu grows around it. As a result, demand and revenue share are concentrating around platforms with the broadest approved anatomical range, and the forecast tilts toward vendors with active fenestrated and branched graft development programmes rather than single-configuration standard graft manufacturers. For instance, in March 2025, W. L. Gore, United States, received FDA approval for four new large-diameter tapered designs for its GORE TAG Conformable Thoracic Stent Graft, one of a growing menu of design variants extending the same core platform’s treatable anatomy range without a new device category submission. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the multi-decade clinical shift from open surgical aneurysm repair toward endovascular repair as the default approach for patients with suitable anatomy. Endovascular repair’s lower peri-operative mortality and faster recovery work as an adoption driver only where anatomy permits stent graft deployment, and this anatomical constraint is precisely what fenestrated and branched graft engineering has been narrowing over time, so clinical outcomes advantage and anatomical eligibility expansion move together to drive procedure conversion. Since the first FDA approval of a thoracic stent graft in 2005, the covered stent graft category has expanded from treating only straightforward tubular aneurysm anatomy to addressing complex juxtarenal, pararenal, and thoracoabdominal configurations through fenestrated and branched design innovation. The recent record shows the pace. W. L. Gore received FDA approval in March 2025 for four new large-diameter tapered designs for its GORE TAG Conformable Thoracic Stent Graft, expanding the anatomical range treatable with an established platform first approved in 2019. The effect on the market is that the population of aneurysm patients eligible for endovascular rather than open repair continues to expand as device design innovation narrows the anatomical exclusion criteria. These are some of the key factors driving revenue growth of the market.

The second driver is the engineering advance of fenestrated and branched graft designs that preserve blood flow to visceral branch vessels during aneurysm repair. Complex aneurysms involving the renal, mesenteric, or celiac arteries cannot be treated with a standard tubular graft without occluding critical branch vessels, and fenestrated and branched designs solve this by incorporating reinforced openings or side branches through which additional covered stents are deployed to preserve flow, so anatomical complexity and device engineering sophistication have advanced together. Multiple commercially available and custom-manufactured branched and fenestrated stent graft systems, including devices from Cook Medical, Gore, Terumo Aortic, and Medtronic, now address thoracoabdominal aortic aneurysm anatomy that would otherwise require high-risk open surgical repair or be considered unsuitable for intervention. The effect on the market is that fenestrated and branched graft procedures represent the fastest-growing segment of covered stent revenue precisely because they address previously unaddressed complex anatomy rather than substituting for existing standard graft procedures. These are some of the key factors driving revenue growth of the market.

“W. L. Gore’s March 2025 FDA approval of four new large-diameter tapered designs for its GORE TAG Conformable Thoracic Stent Graft extended an established platform first approved in 2019, illustrating how covered stent vendors expand addressable patient anatomy through incremental design approval rather than new device category submissions.”

The third driver is the steady FDA approval cadence for expanded sizing, tapering, and design variants that extend an already-approved covered stent graft platform’s treatable anatomy range. Expanding an approved platform’s size and design menu works only if each new variant undergoes its own regulatory review, and this incremental approval pathway is faster and lower-risk than establishing an entirely new device category, so vendors with active design variant pipelines can expand their addressable patient population faster than competitors relying solely on new platform launches. W. L. Gore’s March 2025 approval of four new large-diameter tapered designs for the GORE TAG Conformable Thoracic Stent Graft illustrates this pattern, extending an established platform’s applicability to a broader range of patient aortic diameters without a new device category submission. The effect on the market is that established covered stent graft vendors with active design variant development programmes are capturing disproportionate revenue growth relative to their initial platform approval alone. These are some of the key factors driving revenue growth of the market.

However, the covered stent market faces severe adoption constraints from the significant capital, training, and manufacturing lead-time investment required for fenestrated and branched graft procedures, and from the lifelong surveillance burden covered stent grafts impose on patients and health systems. Because fenestrated and branched graft procedures require advanced pre-operative imaging and planning, custom or semi-custom device manufacturing lead times that can extend treatment timelines, and specialised operator training available at a limited number of centres, adoption remains concentrated at high-volume academic vascular surgery centres rather than broadly distributed across community hospitals, so the addressable complex-anatomy patient population does not convert to covered stent graft revenue as quickly as anatomical eligibility alone would suggest. Device durability and long-term surveillance requirements are a second constraint, because covered stent grafts require lifelong imaging follow-up, typically annual or more frequent computed tomography angiography, to monitor for endoleak, stent migration, and structural integrity, and this ongoing surveillance burden adds cost and complexity for both patients and health systems well beyond the initial procedure cost, so the total cost of ownership is not always fully accounted for in initial procedure-volume-based market projections. Anatomical suitability limitations are the third constraint, since even with fenestrated and branched graft technology, a meaningful share of the most complex aneurysm anatomies, particularly those involving extensive visceral segment disease or unfavourable access vessel anatomy, remain better suited to open surgical repair, capping the total addressable endovascular conversion opportunity below full theoretical potential. These factors substantially limit covered stent market growth over the forecast period.

Based on product type, the global covered stent market is segmented into standard tubular/bifurcated, fenestrated, and branched grafts. Standard tubular and bifurcated grafts hold the largest revenue share, because they address the majority of straightforward infrarenal abdominal aortic aneurysm anatomy, which suits the established, high-volume endovascular aneurysm repair procedure base. Fenestrated grafts remain the established solution for juxtarenal and pararenal anatomy requiring renal artery preservation, and they command a meaningful price premium reflecting their design complexity, but they cannot match the procedure volume of standard grafts given their narrower indicated anatomy. Branched grafts are expected to register the fastest revenue growth rate in the global covered stent market over the forecast period, driven by expanding treatment of thoracoabdominal aortic aneurysms previously considered unsuitable for endovascular repair, which is why Cook Medical, Gore, and Terumo Aortic continue to invest in branched graft platform development.

Based on material, the global covered stent market is segmented into ePTFE-based and polyester (Dacron)-based grafts. ePTFE-based grafts hold a significantly large revenue share, because expanded polytetrafluoroethylene offers the combination of conformability, durability, and low porosity that underpins leading platforms such as the Gore Viabahn and TAG families, which suits the market’s shift toward more anatomically conformable device designs. Polyester-based grafts remain established in specific applications where higher radial strength is prioritised, and they are the material of choice for certain thoracic applications, but they have not matched ePTFE’s adoption growth in the fenestrated and branched graft segments where conformability to complex anatomy matters most.

Based on application, the global covered stent market is segmented into abdominal aortic aneurysm repair, thoracic aortic aneurysm repair, and peripheral and venous applications. Abdominal aortic aneurysm repair holds the largest revenue share, reflecting its position as the original and highest-volume indication for endovascular covered stent graft technology, which suits the market’s deep installed base of standard and fenestrated graft platforms. Peripheral and venous applications are expected to register rapid revenue growth in the global covered stent market over the forecast period, driven by newly approved venous stent platforms such as Gore’s Viabahn Fortegra, approved in January 2026 for deep venous disease, extending covered stent technology into a clinical application area beyond aortic aneurysm repair.

Based on regional analysis, the covered stent market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the highest volume of endovascular aneurysm repair procedures globally and because W. L. Gore, Medtronic, and Cook Medical, the leading global covered stent graft manufacturers, concentrate their commercial and regulatory activity in the country. W. L. Gore’s March 2025 approval of expanded thoracic stent graft tapered designs and its January 2026 approval of the Viabahn Fortegra venous stent both launched first into the United States vascular surgery market. The concentration of FDA approval activity in the United States also means new fenestrated and branched graft design variants are typically approved and adopted in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national covered stent markets within Europe. The region’s well-established vascular surgery infrastructure and CE-marking pathway under the Medical Device Regulation sustain steady demand, though the EU’s more deliberate multi-country regulatory harmonisation process moves more slowly than the FDA’s single-agency approval pathway for incremental design variants. The result is steady rather than rapid growth, shaped more by the region’s already-mature endovascular infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and India represent the three largest national covered stent markets within the region. Rising aneurysm diagnosis rates linked to expanding computed tomography screening availability and growing vascular surgery capacity in China and India are driving new covered stent adoption from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national covered stent markets within the region. Private hospital vascular surgery programmes in both countries are expanding endovascular repair capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised stent graft systems that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban vascular surgery centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial covered stent markets within the GCC. The UAE is the most established covered stent market on the continent given its concentrated private hospital vascular surgery infrastructure, while the wider Gulf states and broader African markets are still building endovascular aneurysm repair capacity from scratch.